Methods for treating triple negative breast cancer using salvianolic acid b

Abstract

The present disclosure provides methods related to treating triple-negative breast cancer (TNBC) in a mammal by administering salvianolic acid B (or a salt or solvate thereof) to promote ceramide-mediated apoptosis. In one form, the ceramide-mediated apoptosis of TNBC cells occurs by decreasing the level of one or more of glucosylceramide synthase and GM3 synthase in the subject through the use of an effective amount of salvianolic acid B. In another aspect, salvianolic acid B or its pharmaceutically acceptable salt or solvate is used as a medicament or in the manufacture of a medicament for treating TNBC.

1 . A method of inducing ceramide-mediated apoptosis by decreasing the level of one or more of glucosylceramide synthase and GM3 synthase in cancer cells of a subject, the method comprising administering to said subject an effective amount of salvianolic acid B or a pharmaceutically acceptable salt thereof. 
     
     
         2 . A method of treating triple-negative breast cancer in a subject in need thereof, the method comprising administering a therapeutically effective amount of salvianolic acid B or a pharmaceutically acceptable salt or solvate thereof to the subject. 
     
     
         3 . The method of  claim 1 , wherein the administering is by at least one of intravenous, oral, parenteral, intraperitoneal, intramuscular, intrathecal, subcutaneous, transdermal, vaginal, rectal, sublingual, buccal, nasal, topical, or inhalation spray administration. 
     
     
         4 . The method of  claim 1 , wherein the salvianolic acid B is administered once a day. 
     
     
         5 . The method of  claim 1 , wherein the salvianolic acid B is administered at a dose of about 0.1 pg to about 500 mg/kg. 
     
     
         6 . The method of  claim 1 , wherein the pharmaceutically acceptable salt is an aluminum salt, calcium salt, iron salt, magnesium salt, manganese salt, or combination thereof. 
     
     
         7 . The method of  claim 1 , wherein the subject is a mammal. 
     
     
         8 . The method of  claim 1 , wherein the subject is a human. 
     
     
         9 . The method of  claim 1 , further comprising administering at least one additional therapy to the subject. 
     
     
         10 . The method of  claim 9 , wherein the at least one additional therapy comprises one or more of radiotherapy, surgery, chemotherapeutic agent, hormone ablation therapy, proapoptosis therapy, and immunotherapy. 
     
     
         11 . The method of  claim 10 , wherein the chemotherapeutic agent comprises doxorubicin. 
     
     
         12 . Use of salvianolic acid B or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for treating cancer by inducing ceramide-mediated apoptosis by decreasing the level of one or more of glucosylceramide synthase and GM3 synthase in cancer cells of a subject. 
     
     
         13 . The use according to  claim 12 , wherein the medicament is formulated for administration by at least one of intravenous, oral, parenteral, intraperitoneal, intramuscular, intrathecal, subcutaneous, transdermal, vaginal, rectal, sublingual, buccal, nasal, topical, or inhalation spray administration. 
     
     
         14 . The use according to  claim 12 , wherein the salvianolic acid B is formulated at a dose of about 0.1 pg to about 500 mg/kg. 
     
     
         15 . The use according to  claim 12 , wherein the pharmaceutically acceptable salt is an aluminum salt, calcium salt, iron salt, magnesium salt, manganese salt, or a combination thereof. 
     
     
         16 . The use according to  claim 12 , wherein the cancer is triple negative breast cancer. 
     
     
         17 . Salvianolic acid B for use as a medicament for treating cancer inducing ceramide-mediated apoptosis by decreasing the level of one or more of glucosylceramide synthase and GM3 synthase in cancer cells of a subject. 
     
     
         18 . The salvianolic acid B of  claim 17 , wherein the salvianolic acid B is formulated for administration by at least one of intravenous, oral, parenteral, intraperitoneal, intramuscular, intrathecal, subcutaneous, transdermal, vaginal, rectal, sublingual, buccal, nasal, topical, or inhalation spray administration. 
     
     
         19 . The use according to  claim 17 , wherein the salvianolic acid B is formulated at a dose of about 0.1 pg to about 500 mg/kg. 
     
     
         20 . The use according to  claim 17 , wherein the pharmaceutically acceptable salt is an aluminum salt, calcium salt, iron salt, magnesium salt, manganese salt, or a combination thereof. 
     
     
         21 . The use according to  claim 17 , wherein the cancer is triple negative breast cancer.